Tianyin Pharmaceutical Co. Inc., of Chengdu, China, said it achieved the public notice (Gong Shi) status for its good manufacturing practice (GMP) certificate of TPI's Qionglai Facility (QLF) from the CFDA. The public notice period lasts for approximately 10 business days which is to be followed by immediate issuance of the GMP certificate. Read More

NEW DELHI – India's attempts to enter into a Regional Comprehensive Economic Partnership (RCEP) deal among 16 countries in Asia are likely to have a significant impact on the biopharma industry, but analysts are divided as to what that will be. Read More

HONG KONG – With the advantage of an English-speaking population, precision manufacturing capabilities and courts dedicated to solving intellectual property matters, Malaysia is quickly emerging as a launch pad for biopharmaceutical companies looking to enter the Asian market and regional companies aiming to expand. Read More

To say that 2014 was a good year for the biopharma industry would be a radical understatement. The flourishing capital markets, the record-breaking number of companies successfully going public via initial public offerings and the validation of scientific breakthroughs that only a few years ago had been mere theories all made for a banner year for the sector. Yet as BioWorld compiled its annual list of the most impactful stories, the top story was one that dominated headlines worldwide: the Ebola virus outbreak in West Africa. Read More

SHANGHAI – China's chief economic planning agency has proposed changes to the way medicine prices are set that will allow more room for market forces and do away with government set price caps. Released in a draft discussion document last month, the new policy is expected to come into force Jan. 1, 2015. Read More